Pgxhealth, LLC

Dogwood Pharmaceuticals, Inc.

Lewis and Clark Pharmaceuticals, Inc.

Adenosine Therapeutics, LLC

Other

University of Virginia Patent Foundation

Emory University

Forest Laboratories Holdings Limited

Dogwoof Pharmaceuticals, Inc.

Trovis Pharmaceuticals, LLC

Guoquan Wang

Robert Douglas Thompson

Jayson Michael Rieger

Anthony Beauglehole

Joel M Linden

Frank Schmidtmann

Shanthi V Sitaraman

The present invention provides N-alkyl 2-(disubstituted)alkynyladenosine-5'-uronamides and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of Aadenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.

[object Object]

The present invention provides xanthine-substituted alkynyl carbamates/reverse carbamates and derivatives thereof and pharmaceutical compositions containing the same that are selective antagonists of Aadenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.

The present invention provides compounds and pharmaceutical compositions that are selective antagonists of Aadenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents. Also provided are processes for the preparation of the compounds and their intermediates.

Methods for the synthesis of unsymmetrical cycloakyl substituted xanthines

The present invention provides compounds and pharmaceutical compositions that are selective antagonists of Aadenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents. Also provided are processes for the preparation of the compounds and their intermediates such as: wherein:

Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines

The present invention provides compounds of the following formula and pharmaceutical compositions that are selective antagonists of Aadenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.

The present invention provides substituted 8-[6-amino-3-pyridyl]xanthines such as the following: and pharmaceutical compositions that are selective antagonists of Aadenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.

Substituted 8-[6-amino-3-pyridyl]xanthines

The present invention relates to method for treating inflammatory bowel disease that includes administration of an effective amount of an antagonist of Aadenosine receptors (ARs).

Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease

The present invention provides compounds and pharmaceutical compositions that are substituted xanthines of formula I: or pharmaceutically acceptable salts thereof, wherein:

Pyrazolyl substituted xanthines

The present invention provides substituted 8-[6-amino-3-pyridyl]xanthines like the compound shown in the following formula: and pharmaceutical compositions that are selective antagonists of Aadenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.

Substituted 8-[6-amino-3pyridyl]xanthines

Selective antagonists of Aadenosine receptors like those of formula I are provided. These compounds and compositions are useful as pharmaceutical agents.

Substituted 8-heteroaryl xanthines

The present invention provides compounds and pharmaceutical compositions that are substituted pyridyl-linked-xanthines of formula I which are selective antagonists of Aadenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.

Pyridyl substituted xanthines

The present invention provides processes for making pyridyl-linked-xanthines of formula VII, from 5,6-diamino-1H-pyrimidine-2,4-diones of formula II and acylating agents of formula VI.  The xanthines are expected to be are selective antagonists of Aadenosine receptors (ARs).

Growing community of inventors

Charlottesville, VA, United States of America

Guoquan Wang